CDSCO Revocation: Eye Drops to Replace Glasses Raises Safety Concerns

Wednesday, 11 September 2024, 01:20

CDSCO has revoked approval for eye drops intended to replace glasses, citing unauthorised promotion and safety concerns. The Drugs Controller General of India (DCGI) highlighted that Entod Pharma failed to respond adequately to raised queries. This decision underscores the oversight necessary in pharmaceutical developments related to eyesight.
Theprint
CDSCO Revocation: Eye Drops to Replace Glasses Raises Safety Concerns

Background on CDSCO's Decision

The Central Drugs Standard Control Organization (CDSCO) has taken a significant step by revoking the approval for eye drops that were marketed as a replacement for glasses. This decision stems from reports of unauthorized promotion and potential safety issues associated with the product.

Concerns Raised by DCGI

The Drugs Controller General of India (DCGI) indicated that Entod Pharma, the manufacturer of the eye drops, did not satisfactorily respond to the queries posed during the review of their promotional practices. Such lack of communication raises serious questions regarding the efficacy and safety of the treatment aimed at enhancing eyesight.

Future Implications for Eye Care Products

This incident serves as a crucial reminder of the need for rigorous regulatory processes in the approval of new health products. The CDSCO’s decision may affect future developments in eye care solutions and emphasizes the importance of adherence to established health policies.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe